Innate Pharma (IPHA) Competitors $1.88 +0.01 (+0.53%) As of 01/6/2025 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IPHA vs. PHVS, ABUS, AUTL, ORIC, STOK, VECT, ANNX, MREO, PHAT, and DNAShould you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Pharvaris (PHVS), Arbutus Biopharma (ABUS), Autolus Therapeutics (AUTL), ORIC Pharmaceuticals (ORIC), Stoke Therapeutics (STOK), VectivBio (VECT), Annexon (ANNX), Mereo BioPharma Group (MREO), Phathom Pharmaceuticals (PHAT), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. Innate Pharma vs. Pharvaris Arbutus Biopharma Autolus Therapeutics ORIC Pharmaceuticals Stoke Therapeutics VectivBio Annexon Mereo BioPharma Group Phathom Pharmaceuticals Ginkgo Bioworks Innate Pharma (NASDAQ:IPHA) and Pharvaris (NASDAQ:PHVS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations. Is IPHA or PHVS more profitable? Innate Pharma's return on equity of 0.00% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets Innate PharmaN/A N/A N/A Pharvaris N/A -38.52%-36.69% Which has higher earnings and valuation, IPHA or PHVS? Innate Pharma has higher revenue and earnings than Pharvaris. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnate Pharma$24.85M6.26-$8.19MN/AN/APharvarisN/AN/A-$109.18M-$2.80-6.45 Does the MarketBeat Community favor IPHA or PHVS? Innate Pharma received 9 more outperform votes than Pharvaris when rated by MarketBeat users. However, 66.04% of users gave Pharvaris an outperform vote while only 57.89% of users gave Innate Pharma an outperform vote. CompanyUnderperformOutperformInnate PharmaOutperform Votes4457.89% Underperform Votes3242.11% PharvarisOutperform Votes3566.04% Underperform Votes1833.96% Which has more volatility and risk, IPHA or PHVS? Innate Pharma has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -3.06, suggesting that its share price is 406% less volatile than the S&P 500. Do insiders & institutionals believe in IPHA or PHVS? 0.2% of Innate Pharma shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 11.8% of Pharvaris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate IPHA or PHVS? Innate Pharma presently has a consensus price target of $11.50, indicating a potential upside of 511.70%. Pharvaris has a consensus price target of $39.25, indicating a potential upside of 117.33%. Given Innate Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Innate Pharma is more favorable than Pharvaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Pharvaris 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to IPHA or PHVS? In the previous week, Pharvaris had 5 more articles in the media than Innate Pharma. MarketBeat recorded 5 mentions for Pharvaris and 0 mentions for Innate Pharma. Pharvaris' average media sentiment score of 1.25 beat Innate Pharma's score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media. Company Overall Sentiment Innate Pharma Neutral Pharvaris Positive SummaryInnate Pharma beats Pharvaris on 11 of the 15 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPHA vs. The Competition Export to ExcelMetricInnate PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.67M$2.97B$5.21B$9.16BDividend YieldN/A1.92%5.30%4.19%P/E RatioN/A45.3587.6417.30Price / Sales6.26443.101,103.40129.08Price / CashN/A174.7343.2637.86Price / Book2.726.295.225.22Net Income-$8.19M-$41.30M$121.39M$226.72M7 Day Performance2.17%6.94%4.75%4.25%1 Month Performance27.89%0.99%21.55%5.48%1 Year Performance-35.62%14.61%32.15%22.16% Innate Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPHAInnate Pharma2.5726 of 5 stars$1.88+0.5%$11.50+511.7%-35.6%$155.67M$24.85M0.00220Gap UpPHVSPharvaris2.8843 of 5 stars$19.31-0.6%$39.25+103.3%-27.8%$614.83MN/A-6.9030Positive NewsABUSArbutus Biopharma2.607 of 5 stars$3.20-0.3%$5.50+71.9%+31.3%$606.37M$6.74M-7.4473Positive NewsAUTLAutolus Therapeutics3.3985 of 5 stars$2.20-2.7%$10.40+372.7%-58.6%$585.41M$10.09M-1.82330Gap UpORICORIC Pharmaceuticals3.4135 of 5 stars$8.22-0.4%$18.29+122.5%-1.2%$580.06MN/A-4.5780STOKStoke Therapeutics4.1994 of 5 stars$10.92-1.3%$21.29+94.9%+109.5%$578.40M$16.74M-5.20100Positive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030ANNXAnnexon2.5653 of 5 stars$5.16-0.6%$15.80+206.2%+9.1%$550.03MN/A-4.9160Positive NewsMREOMereo BioPharma Group2.3569 of 5 stars$3.53-5.4%$7.83+121.9%+52.8%$547.67M$1M0.0040Gap DownPHATPhathom Pharmaceuticals2.4454 of 5 stars$7.95-2.8%$23.00+189.3%-13.3%$543.60M$26.27M-1.40110DNAGinkgo Bioworks0.6463 of 5 stars$9.26-4.1%$4.58-50.6%N/A$532.26M$217.11M-0.711,218 Related Companies and Tools Related Companies PHVS Alternatives ABUS Alternatives AUTL Alternatives ORIC Alternatives STOK Alternatives VECT Alternatives ANNX Alternatives MREO Alternatives PHAT Alternatives DNA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IPHA) was last updated on 1/7/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk says U.S. government is going bankruptIn 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAmazon coin set to soar 25X – starting January 20thThis tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPHA Stock Alerts